trial

PET Scanning in Parkinson s Disease

NCTId NCT00024622
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 502 (actual)
Sponsored by National Institute of Mental Health (NIMH)
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
502 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2002-03-15
Primary completion
—
Eligibility
ALL · 18 Years · 90 Years

Interventions & indications

Drugs
18F-Fluoro-L-dopaO-15 Water

Sponsors

National Institute of Mental Health (NIMH)Lead Sponsor

Investigators

1
Karen F Berman, M.D.Principal Investigator

Sites

1 total
Bethesda, United States

Facts & assertions

3 sourced
Enrollment
502
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
18F-Fluoro-L-dopa
drug
O-15 Water
drug
lead_sponsor
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Nervous System Diseases
indication
investigator
Karen F Berman, M.D.
person